Main Article Content
Neuroendocrine tumors are a diverse group of neoplastic entities with variable degrees of neuroendocrine differentiation that are imaged and, in some cases, treated with nuclear medicine techniques. They are generally uncommon, with an incidence of 50 per million people, and are often considered ‘zebra’ diagnoses. This chapter provides an overview of molecular imaging and therapy of neuroendocrine tumors with radiopharmaceuticals including 111In-octreotide, 123I-mIBG, 131I-mIBG, 68Ga- or 64Cu-DOTATATE, 177Lu DOTATATE, and 18F-FDG. The biodistribution of these radiopharmaceuticals is reviewed along with dosing and, for therapies, the inclusion and exclusion criteria.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.